Here's why Respiri (ASX:RSH) share price is up 10% today

Shareholders might need to catch their breath on this news…

man pointing up at a rising red line which represents a growing share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Respiri Ltd (ASX: RSH) share price is racing higher today after the company announced the addition of another pharmacy network for the sale of its wheezo product.

Upon the commencement of trade this morning, shares in Respiri increased by as much as 24% to 8.7 cents a share. However, the share price has since pulled back from its intraday high.

At the time of writing, the Respiri share price is fetching 7.7 cents, up 10% for yesterday's close.

Sigma Healthcare to stock wheezo

Investors are buying up shares in the respiratory health management company Respiri.

According to the release, the company's asthma management device wheezo will commence sales across pharmacies within the Sigma Healthcare Ltd (ASX: SIG) network Australia-wide.

Sigma's network includes over 570 pharmacies, across Amcal+, Chemist King, Discount Drug Stores, Guardian, Pharmasave, and Wholelife.

Shareholders would be pleased with today's resultant Respiri share price movement. CEO and Managing Director of Respiri, Mr Marjan Mikel stated:

Sigma is a well-known and trusted pharmacy business whose brands have a long history in the Australian market, that patients frequent when seeking healthcare management advice. We look forward to a long and mutually beneficial partnership with Sigma's retail brands that will deliver better health outcomes for patients with asthma.

The company also noted that it is in active discussions with other pharmacy groups. This 'pharmacy pipeline' represents a footprint of over 2,500 stores across Australia.

Respiri gave fair warning that it will provide further announcements once discussions are finalised.

The Respiri share price still struggling

Despite being busy adding several pharmacy brands for wheezo distribution, the Respiri share price is in the deep red year-to-date.

Since the start of the year, the company's shares have fallen 38%. This might be due to investors being turned off the growth in losses.

At the end of 2019, the company made a $6.79 million loss. Unfortunately for shareholders, this loss increased to $12.23 million for the year ending December 2020.  

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

Telix shares in focus as the company meets guidance

More good news from the drug developer.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Good news out of China has this drug company's shares higher

A major new market will open up following this approval.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

This rising ASX 200 stock isn't done yet – or is it?

Inching closer to FDA approval, the share price is falling. Analysts still see 21% to 106% upside.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »